Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001865154 | SCV002123648 | uncertain significance | Methylmalonic aciduria and homocystinuria type cblF | 2022-03-23 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0"). This variant has not been reported in the literature in individuals affected with LMBRD1-related conditions. This variant is present in population databases (rs761378514, gnomAD 0.0009%). This sequence change replaces glutamic acid, which is acidic and polar, with glycine, which is neutral and non-polar, at codon 526 of the LMBRD1 protein (p.Glu526Gly). |
Ambry Genetics | RCV003355576 | SCV004072133 | uncertain significance | Inborn genetic diseases | 2023-06-27 | criteria provided, single submitter | clinical testing | The c.1577A>G (p.E526G) alteration is located in exon 16 (coding exon 16) of the LMBRD1 gene. This alteration results from a A to G substitution at nucleotide position 1577, causing the glutamic acid (E) at amino acid position 526 to be replaced by a glycine (G). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |